-
Mashup Score: 1
“Much more research” is needed to advance the adjuvant treatment of patients with kidney cancer, according to an expert from the Royal Free London NHS Foundation Trust.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Age a Significant Risk Factor for Kidney Function Decline Following Radical Nephrectomy - 1 year(s) ago
The findings indicate that nephron sparing management should be prioritized in elderly patients with kidney cancer when it is safe and feasible, according to the study authors.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
An expert from the University of Texas Southwestern Medical Center in Dallas describes the efficacy of stereotactic radiation in the treatment of patients with metastatic kidney cancer.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0How SBRT Has Evolved Over the Decades to Manage Kidney Cancer - 1 year(s) ago
An expert from the University of Texas Southwestern Medical Center in Dallas gives an overview of the multimodal use of stereotactic radiation for the treatment of patients with metastatic kidney cancer.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0JELMYTO Virtual Booth - 1 year(s) ago
JELMYTO by Urogen
Source: experience.jelmyto.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Review Finds No Association Between Higher BMI and Decreased Kidney Function Following Partial Nephrectomy for Kidney Cancer - 1 year(s) ago
According to a retrospective chart review, there was no significant correlation between BMI and changes in renal function among patients who underwent partial nephrectomy for the treatment of kidney cancer.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Follow-Up Data Show Tazemetostat Remains Safe, Elicits Benefit in Patients With Prostate Cancer - 1 year(s) ago
At a median follow-up of 17.4 months, half of the enrolled patients with metastatic castration-resistant prostate cancer experienced a decrease in PSA level from baseline following treatment with tazemetostat in combination with abiraterone acetate or enzalutamide.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
All patients with chemo-naïve metastatic castration-resistant prostate cancer experienced PSA decline, and half the cohort experienced a PSA decline greater than 50% after treatment with a novel PSMA-targeted radionuclide therapy.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0JELMYTO Virtual Booth - 1 year(s) ago
JELMYTO by Urogen
Source: experience.jelmyto.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Neoadjuvant Axitinib May Reduce Size of Complex Kidney Masses Enough to Permit Partial Nephrectomy in Cases of Kidney Cancer - 1 year(s) ago
The findings, according to the lead study author from UC San Diego School of Medicine, are a proof of concept and need to be confirmed in a phase 2 trial.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
“Much more research” is needed to advance the adjuvant treatment of patients with kidney cancer, according to an expert from the Royal Free London NHS Foundation Trust. #kicsm #SUO2022 | @RoyalFreeNHS https://t.co/q9iN3PUuSy https://t.co/rbWa5yValJ